Drugs / JS015
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05770310 | Feb 2023 → Feb 2024 | cancer | Shanghai Junshi Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06370754 | Apr 2024 → Apr 2026 overdue | malignant pancreatic neoplasm | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06139211 | Jan 2024 → Nov 2025 overdue | neoplasm | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06885385 | Apr 2025 → Nov 2026 expected | colorectal cancer | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JS015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06370754 ↗ |
| Route | Intravenous | “The administration method of JS015 is intravenous infusion.” NCT05770310 ↗ |